The medical management of adolescent heroin dependence

Current psychiatry reports

Volumn 2, Issue 6, 2000, Pages 527-530

  Rowan, Amy B ^a   Fudala, Paul J ^b   Mulligan, James ^c  

^a Treatment Research Center   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Caron Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; HEROIN DEPENDENCE; HUMAN; PATIENT CARE; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; CLINICAL TRIALS; CLONIDINE; HEROIN DEPENDENCE; HUMANS; NARCOTIC ANTAGONISTS; NARCOTICS; PATIENT CARE TEAM; SYMPATHOLYTICS; TREATMENT OUTCOME;

EID: 0034564187     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-000-0013-7     Document Type: Review

References (27)

1. 1. Drug Use by American Young People Begins to Turn Downward. The Monitoring the Future Study. University of Michigan News and Information Service. December 18, 1998.
2. 2. Arrestee Drug Abuse Monitoring Program (ADAM): 1998 Annual Report on Drug Use Among Adult and Juvenile Arrestees. A Program of the National Institute of Justice. April, 1999:62.
3. 3. Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington, DC: American Psychiatric Press; 1994.
4. 4. Crome IB, Christian J, Green C: Tip of the national iceberg? Profile of adolescent patients prescribed methadone in an innovative community drug service. Drugs: Education, Prevention and Policy 1998, 5(2).
5. 5. CJ Hopfer SK Mikulich TJ Crowley 2000 Heroin use among adolescents in treatment for substance use disorders J Am Acad Child Adolescent Psychiatry 39 1316 1323 10.1097/00004583-200010000-00021 1:STN:280:DC%2BD3cvns1Cguw%3D%3D This is one of the first reports in 25 years to examine the substance use characteristics of US adolescents in the treatment of heroin use. This article also examines the Treatment Episode Date Set for trends in the number of adolescents admitted to substance abuse treatment centers and for changes in the routes of heroin administration Hopfer CJ, Mikulich SK, Crowley TJ: Heroin use among adolescents in treatment for substance use disorders. J Am Acad Child Adolescent Psychiatry 2000, 39:1316–1323. This is one of the first reports in 25 years to examine the substance use characteristics of US adolescents in the treatment of heroin use. This article also examines the Treatment Episode Date Set for trends in the number of adolescents admitted to substance abuse treatment centers and for changes in the routes of heroin administration.
6. 6. Code of Federal Regulations 21 Part 291. Drugs Used for Treatment of Narcotic Addicts, April 1, 2000 Edition.
7. 7. MS Gold DE Redmond HD Kleber 1978 Clonidine blocks acute opiate withdrawal symptoms Lancet 16 599 601 10.1016/S0140-6736(78)92823-4 Gold MS, Redmond DE, Kleber HD: Clonidine blocks acute opiate withdrawal symptoms. Lancet 1978, 16:599–601.
8. 8. MS Gold 1993 Opiate addiction and the locus coeruleus Psychiatr Clin North Am 16 61 73 8456048 1:STN:280:DyaK3s3gsFKisg%3D%3D Gold MS: Opiate addiction and the locus coeruleus. Psychiatr Clin North Am 1993, 16:61–73.
9. 9. DS Charney DE Sternberg HD Kleber 1981 The clinical use of clonidine in abrupt withdrawal from methadone Arch Gen Psychatry 38 1273 1277 1:STN:280:DyaL38%2FmslagsQ%3D%3D Charney DS, Sternberg DE, Kleber HD, et al.: The clinical use of clonidine in abrupt withdrawal from methadone. Arch Gen Psychatry 1981, 38:1273–1277.
10. 10. HD Kleber CE Riordan B Rounsaville 1985 Clonidine in outpatient detoxification from methadone maintenance Arch Gen Psychiatry 42 391 394 3977557 1:STN:280:DyaL2M7kvVertA%3D%3D Kleber HD, Riordan CE, Rounsaville B, et al.: Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry 1985, 42:391–394.
11. 11. J Cami S Torres de L San 1985 Efficacy of clonidine and methadone in the rapid detoxification of patients dependent on heroin Clin Pharmacol Ther 38 336 341 4028630 1:STN:280:DyaL2M3otlGntw%3D%3D 10.1038/clpt.1985.182 Cami J, de Torres S, San L, et al.: Efficacy of clonidine and methadone in the rapid detoxification of patients dependent on heroin. Clin Pharmacol Ther 1985, 38:336–341.
12. 12. L San J Cami JM Peri 1990 Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial Br J Addict 85 141 147 1968773 10.1111/j.1360-0443.1990.tb00634.x 1:STN:280:DyaK3c7otFKmsg%3D%3D San L, Cami J, Peri JM, et al.: Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. Br J Addict 1990, 85:141–147.
13. 13. AM Washton RB Resnick 1981 The clinical use of clonidine in outpatient detoxification from opiates Prog Clin Biol Res 71 277 284 7330080 1:STN:280:DyaL387islKmuw%3D%3D Washton AM, Resnick RB: The clinical use of clonidine in outpatient detoxification from opiates. Prog Clin Biol Res 1981, 71:277–284.
14. 14. AM Washton RB Resnick 1982 Outpatient opiate detoxification with clonidine J Clin Psychiatry 43 6 6 Washton AM, Resnick RB: Outpatient opiate detoxification with clonidine. J Clin Psychiatry 1982, 43:6.
15. 15. WR Martin CG Eades JA Thompson 1976 The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog J Pharmacol Exp Ther 197 517 532 945347 1:CAS:528:DyaE28XltlOhurw%3D Martin WR, Eades CG, Thompson JA, et al.: The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976, 197:517–532.
16. 16. DR Jasinski JS Pevnick JD Griffith 1978 Human pharmacology and abuse potential of the analgesic buprenorphine. A potential agent for treating narcotic addiction Arch Gen Psychiatry 35 501 516 215096 1:CAS:528:DyaE1cXktFOitbw%3D Jasinski DR, Pevnick JS, Griffith JD: Human pharmacology and abuse potential of the analgesic buprenorphine. A potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978, 35:501–516.
17. 17. JM Hambrook MJ Rance 1976 The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics Opiates and Endogenous Opioid Peptides Elsevier/North Holland Biomedical Press Amsterdam 295 299 Hambrook JM, Rance MJ: The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. In Opiates and Endogenous Opioid Peptides. Amsterdam: Elsevier/North Holland Biomedical Press; 1976, 295–299.
18. 18. JW Lewis 1985 Buprenorphine Drug Alcohol Depend 14 363 372 2986930 10.1016/0376-8716(85)90067-5 1:CAS:528:DyaL2MXkvVWis7c%3D Lewis JW: Buprenorphine. Drug Alcohol Depend 1985, 14:363–372.
19. 19. RA Lloyd RN Katon RL DuPont 1974 Evolution of a treatment approach for young heroin addicts. comparison of three treatment modalities Int J Addict 9 229 239 4430521 1:STN:280:DyaE2M%2FktVGgsw%3D%3D Lloyd RA, Katon RN, DuPont RL: Evolution of a treatment approach for young heroin addicts. comparison of three treatment modalities. Int J Addict 1974, 9:229–239.
20. 20. Nightingale SL, Wurmser L, Platt PC, Michaux WW: Adolescents on methadone: preliminary observations. Proceedings from the 3rd Annual Conference on Methadone Treatment, National Conference on Methadone Treatment, 1970, 91.
21. 21. Millman RB, Nyswander ME: Slow detoxification of adolescent heroin addicts in New York City. Proceedings from the 3rd Annual Conference on Methadone Treatment. National Conference on Methadone Treatment, 1970, 88.
22. 22. Vandervort WJ: Treatment of drug abuse in adolescents. Proceedings of the 3rd Annual Conference on Methadone Treatment, 1970, 87–88.
23. 23. Schooff KG, Stanczak SA: A treatment program for young heroin addicts. Proceedings of the 4th National Conference on Methadone Treatment. New York National Association for Prevention of Addiction to Narcotics, 1972, 457.
24. 24. GG De Angelis WX Lehmann 1973 Adolescents and short term, low dose methadone maintenance Int J Addict 8 853 863 1:STN:280:DyaE2c7htFejsA%3D%3D De Angelis GG, Lehmann WX: Adolescents and short term, low dose methadone maintenance. Int J Addict 1973, 8:853–863.
25. 25. DR Jasinski PJ Fudala RE Johnson 1989 Sublingual versus subcutaneous buprenorphine in opiate abusers Clin Pharmacol Ther 45 513 519 2721107 1:CAS:528:DyaL1MXksFShtLk%3D 10.1038/clpt.1989.66 Jasinski DR, Fudala PJ, Johnson RE: Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin Pharmacol Ther 1989, 45:513–519.
26. 26. NK Mello JH Mendelson JC Kuehnle 1982 Buprenorphine effects on human heroin self-administration: an operant analysis J Pharmacol Exp Ther 223 30 39 7120124 1:CAS:528:DyaL3sXjvVU%3D Mello NK, Mendelson JH, Kuehnle JC: Buprenorphine effects on human heroin self-administration: an operant analysis. J Pharmacol Exp Ther 1982, 223:30–39.
27. 27. CP O’Brien JW Cornish 1999 Opioids: antagonists and partial agonists. Textbook of Substance Abuse Treatment edn 2 American Psychiatric Press Washington, DC This is an excellent recent review of the pharmacology of opioid antagonists and partial µ-opioid agonist medications that are used or have the potential to treat opioid dependence. Drugs such as naltrexone, naloxone, and buprenorphine are reviewed O’Brien CP, Cornish JW: Opioids: antagonists and partial agonists. Textbook of Substance Abuse Treatment, edn 2. Washington, DC: American Psychiatric Press; 1999. This is an excellent recent review of the pharmacology of opioid antagonists and partial µ-opioid agonist medications that are used or have the potential to treat opioid dependence. Drugs such as naltrexone, naloxone, and buprenorphine are reviewed.